Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
Rhea-AI Summary
Adlai Nortye (NASDAQ: ANL) announced that the first U.S. patient has been dosed in the intermittent weekly (QW) arm of its ongoing global Phase 1 trial of AN9025, a pan-RAS(ON) inhibitor for advanced or metastatic solid tumors with RAS mutations.
The first-in-human, multicenter, open-label study is evaluating safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025. Both the once-daily (QD) and QW dose-escalation arms are now enrolling. Based on preclinical data, the company believes intermittent dosing may widen the therapeutic window, and it plans to share initial Phase 1 QD arm data in 1H27, with a potential early look at QW data.
The trial is being conducted as a multi-regional clinical trial in collaboration with Jiangsu Aosaikang Pharmaceutical (ASK Pharm), under a license agreement in which Adlai Nortye holds ex-China rights and ASK Pharm retains rights in mainland China, Hong Kong and Macao.
Positive
- First patient dosed in intermittent weekly (QW) AN9025 arm in the U.S.
- Both QD and QW arms of the AN9025 Phase 1 trial are now enrolling
- Global multi-regional Phase 1 trial underway for RAS-mutated advanced or metastatic solid tumors
- Adlai Nortye retains ex-China rights to AN9025 under license with ASK Pharm
- Planned initial Phase 1 QD data readout targeted for 1H27
Negative
- Program remains in Phase 1, focused on first-in-human safety and dose escalation
- Initial QD arm data not expected until 1H27, implying a long development timeline
Market reaction after Phase 1 dosing milestone: ANL +6.77% in the Jul 16 session
In the Jul 16 session, ANL gained 6.77%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -4.0% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | AN9025 trial start | Positive | +3.9% | First patient dosed in global Phase 1 trial of AN9025 for RAS tumors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior AN9025 clinical-trial news prompted a positive next-day move in the shares.
Key Terms
pan-ras(on) inhibitor medical
therapeutic window medical
pharmacokinetics medical
multi-regional clinical trial medical
open-label medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
First patient dosed in intermittent QW dosing arm with AN9025
Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data
Both QD and QW arms are now enrolling
SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in the intermittent weekly dosing (QW) arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor.
“Dosing the first U.S. patient with AN9025 on an intermittent weekly schedule is a significant milestone and advances our clinical strategy to evaluate AN9025 with a differentiated approach. We believe based on our preclinical data that weekly dosing could widen the therapeutic window, enabling higher dosing and/or improving tolerability and combinability by giving normal tissue a break while maintaining tumor RAS-signaling inhibition,” said Dr. Archie Tse, President, Head of Research and Development at Adlai Nortye. “We look forward to efficiently progressing the global clinical development of AN9025 and generating meaningful data to support its future advancement. We continue to plan to share initial Phase 1 dose escalation data in 1H27 from the QD arm, with a potential early look at the QW arm.”
The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. This trial is being conducted by Adlai Nortye in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (“ASK Pharm”) as a multi-regional clinical trial (“MRCT”) pursuant to a license agreement, under which Adlai Nortye retains ex-China rights to AN9025, while ASK Pharm holds rights in mainland China, Hong Kong and Macao. With this announcement, both the QD and QW dose escalation arms are currently enrolling.
About AN9025
AN9025 is an oral small molecule pan-RAS(ON) inhibitor with best-in-class potential, designed to target a broad spectrum of RAS mutations across various tumor types. Preclinical studies have demonstrated that AN9025 effectively inhibits RAS-mutant cancers with potent and durable efficacy, including pancreatic, lung, and colorectal adenocarcinomas, and shows comparable or superior results relative to a benchmark agent of the same class.
About Adlai Nortye
Adlai Nortye (NASDAQ: ANL) is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The company is building a rich and robust pipeline of drug candidates covering two key therapeutic areas:
1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company's proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site.
2) Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells, and AN4005, a first-in-class oral PD-L1 inhibitor.
Forward-Looking and Cautionary Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.
The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company's preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company's therapeutic candidates; the Company's ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Contacts:
Investor Relations:
ir@adlainortye.com
